share_log

424B3: Prospectus

424B3: Prospectus

424B3：募资说明书
美股SEC公告 ·  2024/11/04 14:24

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals has filed a prospectus with the SEC under Rule 424(b)(3) for the potential offering of up to $100,000,000 in securities, which may include common stock, preferred stock, warrants, and units. The prospectus outlines the general terms of these securities and indicates that specific details of any offering, including amounts, prices, and terms, will be provided in supplemental filings. The company's common stock is traded on The Nasdaq Global Market under the symbol 'CDT.' As of October 16, 2024, the last reported sale price of Conduit Pharmaceuticals' common stock was $0.114. The company has not sold any securities under the registration statement in the 12 months preceding the date of the prospectus. The prospectus also includes risk factors, such as the need for additional capital and the dependence on the successful development, regulatory approval, and commercialization of its clinical assets. The company has identified material weaknesses in its internal control over financial reporting and is dependent on third-party agreements for licensing its clinical assets.
Conduit Pharmaceuticals has filed a prospectus with the SEC under Rule 424(b)(3) for the potential offering of up to $100,000,000 in securities, which may include common stock, preferred stock, warrants, and units. The prospectus outlines the general terms of these securities and indicates that specific details of any offering, including amounts, prices, and terms, will be provided in supplemental filings. The company's common stock is traded on The Nasdaq Global Market under the symbol 'CDT.' As of October 16, 2024, the last reported sale price of Conduit Pharmaceuticals' common stock was $0.114. The company has not sold any securities under the registration statement in the 12 months preceding the date of the prospectus. The prospectus also includes risk factors, such as the need for additional capital and the dependence on the successful development, regulatory approval, and commercialization of its clinical assets. The company has identified material weaknesses in its internal control over financial reporting and is dependent on third-party agreements for licensing its clinical assets.
Conduit Pharmaceuticals已根据424(b)(3)条款向美国证券交易委员会提交了一份拟议书，用于可能发行高达1亿美元的证券，包括普通股、优先股、warrants和units。拟议书概述了这些证券的一般条款，并指出任何发行的具体细节，包括金额、价格和条款，将在补充备案中提供。该公司的普通股在纳斯达克全球市场上以'CDt'标的交易。截至2024年10月16日，Conduit Pharmaceuticals普通股的最新报价为0.114美元。该公司在拟议书日期前12个月内未根据注册声明出售任何证券。拟议书还包括风险因素，例如需要额外资本以及依赖于其临床资产的成功开发、监管批准和商业化。该公司已确定其财务报告内部控制存在重大弱点，并依赖于第三方协议许可其临床资产。
Conduit Pharmaceuticals已根据424(b)(3)条款向美国证券交易委员会提交了一份拟议书，用于可能发行高达1亿美元的证券，包括普通股、优先股、warrants和units。拟议书概述了这些证券的一般条款，并指出任何发行的具体细节，包括金额、价格和条款，将在补充备案中提供。该公司的普通股在纳斯达克全球市场上以'CDt'标的交易。截至2024年10月16日，Conduit Pharmaceuticals普通股的最新报价为0.114美元。该公司在拟议书日期前12个月内未根据注册声明出售任何证券。拟议书还包括风险因素，例如需要额外资本以及依赖于其临床资产的成功开发、监管批准和商业化。该公司已确定其财务报告内部控制存在重大弱点，并依赖于第三方协议许可其临床资产。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Passage BIO
    PASG
    -- 0.830
    MiNK Therapeutics
    INKT
    -- 1.010
    Klotho Neurosciences
    KLTO
    -- 0.700
    Revelation Biosciences
    REVB
    -- 0.6570
    居里
    CRIS
    -- 4.2400

    解锁榜首股票